SynthesisJournal of translational medicine2026
The neuropeptide in ischemic brain injury: insights, challenges, and horizon of targeted interventions.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral ischemic stroke (CIS) is a highly lethal and disabling global disease with complex pathological mechanisms that pose significant challenges for effective treatment. In recent years, endogenous neuropeptides have emerged as critical signaling molecules, attracting increasing attention for their regulatory roles in the pathophysiology of CIS.
methodsThis systematic review examines the dynamic functions of various neuropeptides—including opioid peptides, oxytocin, orexin, pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), cocaine- and amphetamine-regulated transcript (CART) peptide, substance P (SP), galanin, neuropeptide Y (NPY), and vasopressin—across the different pathological stages of CIS (hyperacute, acute, subacute, and chronic phases). It also evaluates therapeutic strategies targeting the neuropeptide system, including associated challenges and future directions.
resultsNeuropeptides exhibit stage-dependent regulatory roles in CIS, influencing processes such as neuroprotection, inflammation, excitotoxicity, and recovery. The review synthesizes evidence on how these molecules modulate stroke pathology, highlighting their potential as therapeutic targets.
conclusionsTargeting the neuropeptide system offers a promising avenue for precision therapies in ischemic stroke, though challenges such as delivery methods and translational research must be addressed. Future directions include developing receptor subtype-specific drugs and novel drug delivery systems to enhance clinical efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.